After 25+ years of significant cancer research, the North Shore CCOP is applying for its fifth 5-year renewal. In the past 4 years, the North Shore Long Island Jewish Health System's (NSLIJHS) research program screened 2,829 patients and enrolled 1,233 on cancer treatment, prevention and control trials, meeting or exceeding the required annual 50 credits for each grant year. The North Shore CCOP currently offers local access to, and data management support for almost 50 cancer research studies open to accrual through its affiliations with the Cancer and Leukemia Group B, the Radiation Therapy Oncology Group, the National Surgical Adjuvant Breast and Bowel Project, the University of Rochester Cancer Center, the Fox Chase Cancer Center Research Base and the Wake Forest Cancer Center. The goals for the upcoming grant cycle are (1) Increased patient recruitment including improved minority and female enrollment;(2) Increased utilization of community practices and outlying institutions;and (3) Increased CCOP participation from specialists other than medical oncologists, especially in cancer control and prevention trials. The North Shore CCOP has matured into a multidisciplinary research unit. It includes medical, radiation and surgical oncologists from Nassau, Suffolk and Queens Counties in New York. Additional full time support staff including ONS and SOCRA certified nurses, data managers, research coordinators, regulatory staff and others participate at a variety of locations across the catchment area. In 2008, NSLIJHS hospitals accounted for 24% percent of all cancer-related inpatient and ambulatory surgery discharges in New York's Queens, Nassau and Suffolk counties. In 2008, more than 17,650 patients discharged from NSLIJHS hospitals were diagnosed with or treated for cancer. The North Shore CCOP is an integral part of NSLIJHS's cancer services and strives annually to deliver excellent patient care through clinical trials that meet or exceed the National Cancer Institute's clinical trials program requirements.

Public Health Relevance

According to the """"""""Annual Report to the Nation on the Status of Cancer, 1975-2005"""""""", cancer death rates from 2002-2004 decreased at an average rate almost double the annual per year decrease from 1993-2002. This observed decrease in the incidence and death rates from all cancers combined is highly encouraging. However, ongoing research is needed to improve our current methods of prevention, early detection, and treatment.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (J1))
Program Officer
O'Mara, Ann M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Feinstein Institute for Medical Research
United States
Zip Code
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Eisfeld, A-K; Mrózek, K; Kohlschmidt, J et al. (2017) The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia 31:2211-2218
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38

Showing the most recent 10 out of 111 publications